Novo-Nordisk A/S (NVO) Stock Price

NVOStock
$45.6115.80%52W
Market Cap$201.64B
P/E12.96x
PEG Ratio3.14
Div yield1.00%
Beta1.92

NVO Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-15.80%
Price vs S&P 500 (4W)-3.79%
PEG Ratio3.14
VGM Score55.72
P/E Ratio (Annual)12.96x
Indicated Dividend Yield (Annual)1.00%

NVO Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026$0.78$0.96+24.01%(+$0.19)
Q1 2026$1.08$1.03-4.75%(-$0.05)
Q4 2025$0.92$0.94+2.34%(+$0.02)
Q3 2025$0.66$0.70+6.05%(+$0.04)
Q2 2025$0.94$0.93-0.74%(-$0.01)

NVO Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
3.38
3.38
3.41
3.41

Industry Peers — Pharmaceuticals(570)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
NVONovo-Nordisk A/S
BCC$45.61
LLYEli Lilly & Co.DBC$1174.61
JNJJohnson & JohnsonDCB$268.04
ABBVABBVIE INC.DCB$255.48
MRKMerck & Co., Inc.DCB$148.35
NVSNovartis AGCCC$153.81
AZNAstraZeneca PLCCBC$162.70
ABTAbbott LaboratoriesCCC$112.47
PFEPfizer Inc.CDB$27.96
VRTXVertex Pharmaceuticals IncDCB$541.69
BMYBristol-Myers Squibb Co.BBB$66.58

About Novo-Nordisk A/S

Novo Nordisk is the global leader in diabetes care, commanding approximately one-third of the branded diabetes treatment market. The Danish company manufactures insulins, GLP-1 therapies, oral antidiabetics, and obesity treatments. Its smaller biopharmaceutical segment, representing less than 10% of revenue, develops protein therapies for hemophilia and related disorders.